Thema: US00287Y1091
AbbVie Inc., US00287Y1091
AbbVie Inc. US00287Y1091 NYSE Handelssaal Editorial Fotografie Händler Pharma Aktiencharts grüne Kurven auf Monitoren - Foto: THN
AbbVie stock: Q3 revenue rises as 2026 guidance moves higher
AbbVie stock advances after the drugmaker lifted its full-year outlook and raised its quarterly dividend. Etentamig also entered FDA review.
ad-hoc-news.de, 30.10.26 16:23 Uhr
AbbVie Inc., US00287Y1091
AbbVie stock: Etentamig filing advances oncology pipeline ...
AbbVie stock enters the FDA review process with a late-stage multiple myeloma candidate designed for monthly dosing. Investors now await regulatory next steps.
ad-hoc-news.de, 30.10.26 11:32 Uhr
AbbVie Inc., US00287Y1091
AbbVie stock: Etentamig filing adds an oncology milestone ...
AbbVie stock trades at EUR 259.90 on October 29, 2026, above the previous report's quoted level. The filing expands its oncology pipeline.
ad-hoc-news.de, 29.10.26 17:54 Uhr
AbbVie Inc., US00287Y1091
AbbVie files etentamig application: what it means for AbbVie ...
Etentamig reached a 74.00 percent response rate versus 45.70 percent in CERVINO. AbbVie stock trades at EUR 256.55 on October 28, 2026.
ad-hoc-news.de, 28.10.26 10:46 Uhr
AbbVie Inc., US00287Y1091
Piper Sandler keeps Buy rating for AbbVie stock at USD 303.00 ...
Revenue reached USD 16.99 billion in the second quarter, up 10.20 percent year over year. AbbVie stock costs EUR 257.05 on October 27, 2026.
ad-hoc-news.de, 27.10.26 17:06 Uhr
AbbVie Inc., US00287Y1091
Piper Sandler reaffirms Buy on AbbVie stock: the price gains ...
The note dated October 26, 2026 names a USD 303.00 target. AbbVie stock costs EUR 258.70, 1.69 percent above the Xetra close.
ad-hoc-news.de, 27.10.26 11:20 Uhr
AbbVie Inc., US00287Y1091
Goldman Sachs lifts target for AbbVie stock to USD 294.00 ...
AbbVie reports on October 30, 2026. AbbVie stock costs EUR 256.45 on October 26, 2026, plus 0.81 percent versus the October 23, 2026 Xetra close.
ad-hoc-news.de, 26.10.26 16:45 Uhr
AbbVie Inc., US00287Y1091
AbbVie wins Crohn's approval: what it means for AbbVie stock ...
AbbVie reported USD 16.99 billion in second-quarter revenue, up 10.20 percent. AbbVie stock costs EUR 255.20 on October 26, 2026, 0.31 percent above Xetra close.
ad-hoc-news.de, 26.10.26 11:25 Uhr
AbbVie Inc., US00287Y1091
AbbVie Inc. stock at EUR 254.95 ahead of the Xetra open: ...
AbbVie develops and sells medicines in immunology oncology neuroscience aesthetics and eye care. At Lang & Schwarz the stock trades pre-market at EUR 254.95 on October 26 ...
ad-hoc-news.de, 26.10.26 07:42 Uhr
AbbVie Inc., US00287Y1091
AbbVie reports data. AbbVie stock trades 0.10 percent above ...
